GLTO - Galecto, Inc.
IEX Last Trade
5.39
0 0%
Share volume: 402
Last Updated: Fri 27 Dec 2024 07:13:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.39
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
14.81%
1 Month
-1.63%
3 Months
-53.71%
6 Months
984.00%
1 Year
658.89%
2 Year
411.32%
Key data
Stock price
$5.39
DAY RANGE
$5.29 - $5.39
52 WEEK RANGE
$0.48 - $14.82
52 WEEK CHANGE
$652.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Hans T. Schambye
Region: US
Website: galecto.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: galecto.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Galecto, Inc. develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the. treatment of myelofibrosis. GB0139, an inhaled. inhibitor of galectin-3 that is in. Phase IIb clinical trials for severe fibrotic lung diseases.
Recent news